Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer

X. Le; S. Popat; J.V. Heymach; H. West; L. Zhang

doi:10.1016/j.esmoop.2025.106027

January 27, 2026ESMO OpenOpen Access

Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer

View Full Paper

Ask AI

Bookmark

Share

Key Points

Acquired resistance in EGFR mutation-positive non-small-cell lung cancer impacts treatment efficacy and survival rates.
Observational analysis highlights that about 50% of patients may develop resistance to standard therapies within 12 months.
Assessment using genomic profiling reveals key biomarkers for monitoring treatment response and resistance mechanisms.
Findings suggest the need for personalized treatment strategies and ongoing monitoring to improve patient outcomes.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Analysis addresses treatment methods for acquired resistance in non-small-cell lung cancer with EGFR mutations, suggesting strategies for better outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Le et al. (2026) studied this question.

synapsesocial.com/papers/69a75b62c6e9836116a22a09 https://doi.org/10.1016/j.esmoop.2025.106027

View Full Paper

Ask AI

Bookmark

Share

Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

More related papers

More from ESMO Open

Keep reading

More related papers

More from ESMO Open